Companies · Pharmaceuticals

Zosano Pharma Corp

FREMONT · Pharmaceuticals

Diligence memoA one-page analyst read on Zosano Pharma Corp — recommendation, valuation, rhythm, risks.
$29.7M
Total raised · real
6
Rounds
25.1×
Latest step-up
Top 28%
Sector rank · raised
Series A
Latest stage · inferred · Fri Aug 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Zosano Pharma Corp looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.31× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
  • Within the normal band (131% of peer median) for its niche.
Dormant
  • Last raise 9.9 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Zosano Pharma Corp is one of 1610 Pharmaceuticals companies tracked from FREMONT. By capital raised it ranks in the upper tier (ahead of 73% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2013-09-09 Raised $3.0M (real) Modeled valuation $115M (est)$3.0M$115MSeed2013Seed · 2014-02-26 Raised $2.5M (real) Modeled valuation $95M (est)$2.5M$95MSeed2014Seed · 2014-12-02 Raised $1.3M (real) Modeled valuation $51M (est)$1.3M$51MSeed2014Series A · 2015-01-30 Raised $15M (real) Modeled valuation $465M (est)$15M$465MSeries A2015Series A · 2015-06-23 Raised $300K (real) Modeled valuation $9.3M (est)$300K$9.3MSeries A2015Series A · 2016-08-19 Raised $7.5M (real) Modeled valuation $233M (est)$7.5M$233MSeries A2016+$2.5M+$1.3M+$15M+$300K+$7.5MCumulative $30M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2013
Seed extension$2.5M · 2014
Seed extension$1.3M · 2014
Series A$15.0M · 2015
Series A extension$300K · 2015
Series A extension$7.5M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$233.4M
Base estimate est.
$8.6M
Conservative case
$1.3B
Upside case
$34.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $115.4M · 2013-09-092013Seed · modeled $95.1M · 2014-02-26Seed · modeled $50.7M · 2014-12-02Series A · modeled $464.6M · 2015-01-30Series A · modeled $9.3M · 2015-06-23Series A · modeled $233.4M · 2016-08-192016
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
9.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$10.1M/yr
Capital velocity
12.8 yr
On record since
2013
First round
6
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.7× above median
This company$29.7M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.5× above median
This company$7.5M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 3.1× above median
This company$233.4M
Sector median$76.1M

Raised more than 73% of sector peers (real $). Modeled value above 71% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #31 of 88.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Arbutus Biopharma Corp · Series A Raised $15.0M · modeled $464.6M (est)Rvc 360, Llc · Series A Raised $15.0M · modeled $464.6M (est)Sterrx, Llc · Series A Raised $18.0M · modeled $464.6M (est)Ribometrix, Inc. · Series A Raised $18.5M · modeled $464.6M (est)Neuraltus Pharmaceuticals, Inc. · Series A Raised $40.6M · modeled $462.7M (est)SiteOne Therapeutics, Inc. · Series A Raised $16.1M · modeled $460.3M (est)Right Value Drug Stores, Inc. · Series A Raised $13.3M · modeled $411.9M (est)USWM Enterprises, LLC · Series A Raised $12.2M · modeled $376.7M (est)Satsuma Pharmaceuticals, Inc. · Series A Raised $12.1M · modeled $375.8M (est)Chase Pharmaceuticals Corp · Series A Raised $26.5M · modeled $370.9M (est)Vitruvias Therapeutics, Inc. · Series A Raised $12.4M · modeled $356.2M (est)Vyome Therapeutics Inc. · Series A Raised $14.5M · modeled $351.1M (est)Zosano Pharma Corp (this company) Raised $29.7M · modeled $233.4M (est)Zosano Pharma Corp
CompanyStageRaised · realValue · estvs peer med.
Arbutus Biopharma CorpSeries A$15.0M$464.6M2.61×
Rvc 360, LlcSeries A$15.0M$464.6M2.61×
Sterrx, LlcSeries A$18.0M$464.6M2.61×
Ribometrix, Inc.Series A$18.5M$464.6M2.61×
Neuraltus Pharmaceuticals, Inc.Series A$40.6M$462.7M2.60×
SiteOne Therapeutics, Inc.Series A$16.1M$460.3M2.59×
Right Value Drug Stores, Inc.Series A$13.3M$411.9M2.31×
USWM Enterprises, LLCSeries A$12.2M$376.7M2.12×
Satsuma Pharmaceuticals, Inc.Series A$12.1M$375.8M2.11×
Chase Pharmaceuticals CorpSeries A$26.5M$370.9M2.08×
Vitruvias Therapeutics, Inc.Series A$12.4M$356.2M2.00×
Vyome Therapeutics Inc.Series A$14.5M$351.1M1.97×
Zosano Pharma Corp this companySeries A$29.7M$233.4M1.31×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2013-09-09$15.2M$115.4M90%
Seed$2.5M2014-02-26$12.5M$95.1M90%
Seed$1.3M2014-12-02$6.7M$50.7M90%
Series A$15.0M2015-01-30$68.2M$464.6M90%
Series A$300K2015-06-23$1.4M$9.3M90%
Series A$7.5M2016-08-19$34.3M$233.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2013-09-09
    • First recorded raise — entered as Seed.
  2. Seed$2.5M2014-02-26
    • Came back fast: 6 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
  3. Seed$1.3M2014-12-02
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
  4. Series A$15.0M2015-01-30
    • Came back fast: 2 mo vs the ~13 mo sector norm.
    • Round 11.3× larger than the prior — scaling up.
  5. Series A$300K2015-06-23
    • Came back fast: 5 mo vs the ~13 mo sector norm.
    • Round 50.0× smaller than the prior — bridge or down round.
  6. Series A$7.5M2016-08-19
    • Raised 14 mo later, in step with the ~13 mo sector norm.
    • Round 25.1× larger than the prior — scaling up.
Intelligence
2017 ~Q1
Modeled next raise · ~7mo cadence
$22.6M
Modeled next size est.range $14.7M$36.2M
25.1×
Last step-up
$10.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John Walker16 other2016-08
James Barrett5 other2013-09
M. James Barrett5 other2014-02
Christopher Krueger3 other2013-09
Kleanthis Xanthopoulos3 other2013-09
Vikram Lamba3 other2013-09
Konstantinos Alataris2 other2016-08
Bruce D. Steel1 other2016-08
Bruce James Steel1 other2014-02
Bruce Steel1 other2013-09
John James Richard1 other2014-02
John Richard1 other2013-09
Joseph P. Hagan1 other2016-08
Kleanthis James Xanthopoulos1 other2014-02
Christopher James Krueger2014-02
Donald D. Kellerman2016-08
Eric D. Scharin2016-08
Georgia D. Erbez2016-08
Haley D. Lewis2016-08
Joseph James Hagan2015-06
Kleanthis D. Xanthopoulos2016-08
Laxmi James Peri2015-06
Nandan James Oza2014-02
Nandan Oza2013-09
Registry & provenance

Zosano Pharma Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1587221
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Zosano, Inc.OtherPre-Seed$365K$8.4Mnetwork6 shared operators
Predictive Biosciences, IncBiotechnologySeries B$26.8M$1.0Bnetwork3 shared operators
Neuraltus Pharmaceuticals, Inc.PharmaceuticalsSeries A$40.6M$462.7Mnetwork1 shared operator · same sector · same stage
Regulus Therapeutics Inc.PharmaceuticalsSeries B$170.5M$672.5Mnetwork2 shared operators · same sector
Harrow Health, Inc.PharmaceuticalsSeries A$29.2M$226.3Msame sector · same stage
Processa Pharmaceuticals, Inc.PharmaceuticalsSeries A$29.0M$238.9Msame sector · same stage
Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.)PharmaceuticalsSeries A$30.5M$334.7Msame sector · same stage
Cocrystal Pharma, Inc.PharmaceuticalsSeries A$28.9M$92.9Msame sector · same stage
Frequently asked
How much funding has Zosano Pharma Corp raised?
Zosano Pharma Corp has raised approximately $29.7M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Zosano Pharma Corp's estimated valuation?
Provath's modeled valuation for Zosano Pharma Corp is approximately $233.4M (modeled range $8.6M–$1.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Zosano Pharma Corp at?
Zosano Pharma Corp's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Aug 19.
What does Zosano Pharma Corp do and where is it based?
Zosano Pharma Corp operates in the Pharmaceuticals sector, based in FREMONT.
Explore related

See where Zosano Pharma Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Zosano Pharma Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.